Shots:
With diverse applications in diagnostic imaging, theragnostics, and targeted therapy, radiopharmaceuticals are gradually tapping into an ocean of unlimited opportunities
By 2030, the radiopharmaceutical market size is expected to grow to $12.18B. In 2023, POINT Biopharma topped the list among radiopharma companies with a market cap of $726.88B followed by Novartis with a market…
Shots:
2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023
PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology
For the complete report with analysis, reach out to us…
Shots:
In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readers
Xtandi is indicated for the treatment of certain prostate cancers
PharmaShots presents a concise take on the key features of Xtandi with…

